Next year, San Diego-based Ligand Pharmaceuticals is hoping to launch a third-generation selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania.
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Hollmer, M. Biotech takes aim at large anti-estrogen markets. Nat Biotechnol 24, 1455–1456 (2006). https://doi.org/10.1038/nbt1206-1455
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1455
- Springer Nature America, Inc.